4'-iodo-4'-deoxydoxorubicinol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

4'-iodo-4'-deoxydoxorubicinol: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID Source	ID
PubMed CID	9874402
MeSH ID	M0171899

Synonyms (7)

Synonym
111865-30-6
4'-deoxy-4'-iododoxorubicinol
4'-iddr
5,12-naphthacenedione, 10-((4-aminotetrahydro-5-iodo-6-methyl-2h-pyran-2-yl)oxy)-8-(1,2-dihydroxyethyl)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-
4'-iodo-4'-deoxydoxorubicinol
(7s,9s)-7-[(2r,4s,5s,6s)-4-amino-5-iodo-6-methyloxan-2-yl]oxy-9-(1,2-dihydroxyethyl)-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione
4/'-iodo-4/'-deoxydoxorubicinol

Research Excerpts

Toxicity

Excerpt	Reference	Relevance
" Treatments induced a significant widening of the S alpha T segment, but I-DXRol was significantly less toxic than I-DXR or DXR."	( Cardiac toxicity and antitumor activity of 4'-deoxy-4'-iodo-doxorubicinol. Bernardini, N; Bevilacqua, G; Danesi, R; Del Tacca, M; La Rocca, RV; Marchetti, A, 1990)	0.28

Pharmacokinetics

Excerpt	Reference	Relevance
"4); the metabolite was cleared from the plasma with an elimination half-life of 15."	( Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humans. Armand, JP; Huet, S; Hurteloup, P; Klink-Alakl, M; Recondo, G; Robert, J, 1992)	0.28
" The pharmacokinetic parameters also implied metabolic differences between species."	( Pharmacokinetics of iododoxorubicin in the rat, dog, and monkey. Basileo, G; Edwards, DM; Efthymiopoulos, C; Fraier, D; Marrari, P; Pianezzola, E; Strolin-Benedetti, M, )	0.13

[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (4)

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	1 (25.00)	18.7374
1990's	3 (75.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (20.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	4 (80.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.	1.97	1	0	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
epirubicin Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.	1.97	1	0	aminoglycoside; anthracycline antibiotic; anthracycline; deoxy hexoside; monosaccharide derivative; p-quinones; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	antimicrobial agent; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
adriamycinol doxorubicinol : A member of the class of tetracenequinones that is the major metabolite of the anthracycline doxorubicin, a chemotherapeutic agent effective against a broad range of malignant neoplasms. It is thought to exhibit cardiotoxic properties.	1.97	1	0	aminoglycoside; anthracycline antibiotic; aromatic ether; deoxy hexoside; p-quinones; phenols; polyol; tetracenequinones	cardiotoxic agent; drug metabolite
4'-deoxy-4'-iododoxorubicin 4'-deoxy-4'-iododoxorubicin: lipophilic derivative of doxorubicin which differs from the parent compound in substitution of hydroxyl group on the daunosamine sugar moiety	4.28	4	1	organoiodine compound; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone
daunorubicinol daunorubicinol: main metabolite of daunomycin. (13S)-13-dihydrodaunorubicin : The (13S)-diastereomer of 13-dihydrodaunorubicin.	1.97	1	0	13-dihydrodaunorubicin
idarubicinol idarubicinol: RN given refers to (7S-(7alpha,9alpha,9(R*))-isomer	1.97	1	0	anthracycline

Condition	Relationship Strength	Studies	Trials
Carcinoma, Epidermoid [description not available]	3.36	1	1
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	3.36	1	1
Carcinoma, Oat Cell [description not available]	1.97	1	0
Glial Cell Tumors [description not available]	2.38	2	0
Cancer of Lung [description not available]	1.97	1	0
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	2.38	2	0
Lung Neoplasms Tumors or cancer of the LUNG.	1.97	1	0
Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)	1.97	1	0

chemdatabank.com